NICE refuses to reconsider Spinraza criteria
NICE is refusing to amend the entry criteria for Spinraza treatment. We are fighting on.
Category: Updates
NICE refuses to reconsider Spinraza criteria
NICE is refusing to amend the entry criteria for Spinraza treatment. We are fighting on.
Spinraza treatment only for some?
We have analysed the NICE/NHS eligibility criteria for Spinraza and we view them as potentially depriving hundreds of children and adults of access to the only treatment. Read on.
Spinraza treatment only for some?
We have analysed the NICE/NHS eligibility criteria for Spinraza and we view them as potentially depriving hundreds of children and adults of access to the only treatment. Read on.
NICE starts appraising Zolgensma to treat spinal muscular atrophy
Closer to a new treatment: NICE has begun the appraisal process of SMA gene therapy Zolgensma.
NICE starts appraising Zolgensma to treat spinal muscular atrophy
Closer to a new treatment: NICE has begun the appraisal process of SMA gene therapy Zolgensma.
Draft Managed Access Agreement for Spinraza has been published
NICE releases the final draft of the Managed Access Agreement. We will challenge some of the treatment criteria it proposes.
Draft Managed Access Agreement for Spinraza has been published
NICE releases the final draft of the Managed Access Agreement. We will challenge some of the treatment criteria it proposes.